Global Biosimilar Insulin Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Description

According to our (Global Info Research) latest study, the global Biosimilar Insulin market size was valued at USD 2632.1 million in 2023 and is forecast to a readjusted size of USD 6421.8 million by 2030 with a CAGR of 13.6% during review period.

Biosimilar insulin is a biological copy of an original insulin and there is increasing interest in developing and using them. Biosimilar insulins (hereafter called biosimilars or follow-on biologics) are designed to be highly similar to the original, or reference, insulin product described in a patent. They are analogous to generic versions of small-molecule drugs and are developed by companies other than the reference product's patent holder. Producers of biosimilars use manufacturing techniques that are similar, but likely not identical to, those used by the original patent holder. Thus, although a biosimilar and its reference insulin product will have the same amino acid sequence, they may differ slightly in their more subtle molecular characteristics and clinical profiles.

Global Biosimilar Insulin key players include Biocon, Gan&Lee, Wockhardt, Eli Lilly, Sanofi etc. Global top three players hold a share over 70%. India is the largest market, with a share about 30%, followed by Southeast Asia and China, both have a share about 40 percent
The Global Info Research report includes an overview of the development of the Biosimilar Insulin industry chain, the market status of Hospital (Biosimilar Insulin Glargine, Biosimilar Insulin Lispro), Retail Pharmacy (Biosimilar Insulin Glargine, Biosimilar Insulin Lispro), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Biosimilar Insulin.

Regionally, the report analyzes the Biosimilar Insulin markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Biosimilar Insulin market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:
The report presents comprehensive understanding of the Biosimilar Insulin market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Biosimilar Insulin industry.

The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Unit), revenue generated, and market share of different by Type (e.g., Biosimilar Insulin Glargine, Biosimilar Insulin Lispro).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Biosimilar Insulin market.

Regional Analysis: The report involves examining the Biosimilar Insulin market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Biosimilar Insulin market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Biosimilar Insulin:
Company Analysis: Report covers individual Biosimilar Insulin manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Biosimilar Insulin This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Distribution Channel (Hospital, Retail Pharmacy).

Technology Analysis: Report covers specific technologies relevant to Biosimilar Insulin. It assesses the current state, advancements, and potential future developments in Biosimilar Insulin areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Biosimilar Insulin market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation
Biosimilar Insulin market is split by Type and by Distribution Channel. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Distribution Channel in terms of volume and value.

Market segment by Type
    Biosimilar Insulin Glargine
    Biosimilar Insulin Lispro
    Other

Market segment by Distribution Channel
    Hospital
    Retail Pharmacy
    Others

Major players covered
    Eli Lilly
    Sanofi
    Gan&Lee
    Tonghua Dongbao
    United Laboratory
    Geropharm
    Biocon
    Wockhardt

Market segment by region, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Biosimilar Insulin product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Biosimilar Insulin, with price, sales, revenue and global market share of Biosimilar Insulin from 2019 to 2024.
Chapter 3, the Biosimilar Insulin competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Biosimilar Insulin breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and distribution channel, with sales market share and growth rate by type, distribution channel, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Biosimilar Insulin market forecast, by regions, type and distribution channel, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Biosimilar Insulin.
Chapter 14 and 15, to describe Biosimilar Insulin sales channel, distributors, customers, research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Biosimilar Insulin
    1.2 Market Estimation Caveats and Base Year
    1.3 Market Analysis by Type
        1.3.1 Overview: Global Biosimilar Insulin Consumption Value by Type: 2019 Versus 2023 Versus 2030
        1.3.2 Biosimilar Insulin Glargine
        1.3.3 Biosimilar Insulin Lispro
        1.3.4 Other
    1.4 Market Analysis by Distribution Channel
        1.4.1 Overview: Global Biosimilar Insulin Consumption Value by Distribution Channel: 2019 Versus 2023 Versus 2030
        1.4.2 Hospital
        1.4.3 Retail Pharmacy
        1.4.4 Others
    1.5 Global Biosimilar Insulin Market Size & Forecast
        1.5.1 Global Biosimilar Insulin Consumption Value (2019 & 2023 & 2030)
        1.5.2 Global Biosimilar Insulin Sales Quantity (2019-2030)
        1.5.3 Global Biosimilar Insulin Average Price (2019-2030)

2 Manufacturers Profiles
    2.1 Eli Lilly
        2.1.1 Eli Lilly Details
        2.1.2 Eli Lilly Major Business
        2.1.3 Eli Lilly Biosimilar Insulin Product and Services
        2.1.4 Eli Lilly Biosimilar Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.1.5 Eli Lilly Recent Developments/Updates
    2.2 Sanofi
        2.2.1 Sanofi Details
        2.2.2 Sanofi Major Business
        2.2.3 Sanofi Biosimilar Insulin Product and Services
        2.2.4 Sanofi Biosimilar Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.2.5 Sanofi Recent Developments/Updates
    2.3 Gan&Lee
        2.3.1 Gan&Lee Details
        2.3.2 Gan&Lee Major Business
        2.3.3 Gan&Lee Biosimilar Insulin Product and Services
        2.3.4 Gan&Lee Biosimilar Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.3.5 Gan&Lee Recent Developments/Updates
    2.4 Tonghua Dongbao
        2.4.1 Tonghua Dongbao Details
        2.4.2 Tonghua Dongbao Major Business
        2.4.3 Tonghua Dongbao Biosimilar Insulin Product and Services
        2.4.4 Tonghua Dongbao Biosimilar Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.4.5 Tonghua Dongbao Recent Developments/Updates
    2.5 United Laboratory
        2.5.1 United Laboratory Details
        2.5.2 United Laboratory Major Business
        2.5.3 United Laboratory Biosimilar Insulin Product and Services
        2.5.4 United Laboratory Biosimilar Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.5.5 United Laboratory Recent Developments/Updates
    2.6 Geropharm
        2.6.1 Geropharm Details
        2.6.2 Geropharm Major Business
        2.6.3 Geropharm Biosimilar Insulin Product and Services
        2.6.4 Geropharm Biosimilar Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.6.5 Geropharm Recent Developments/Updates
    2.7 Biocon
        2.7.1 Biocon Details
        2.7.2 Biocon Major Business
        2.7.3 Biocon Biosimilar Insulin Product and Services
        2.7.4 Biocon Biosimilar Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.7.5 Biocon Recent Developments/Updates
    2.8 Wockhardt
        2.8.1 Wockhardt Details
        2.8.2 Wockhardt Major Business
        2.8.3 Wockhardt Biosimilar Insulin Product and Services
        2.8.4 Wockhardt Biosimilar Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.8.5 Wockhardt Recent Developments/Updates

3 Competitive Environment: Biosimilar Insulin by Manufacturer
    3.1 Global Biosimilar Insulin Sales Quantity by Manufacturer (2019-2024)
    3.2 Global Biosimilar Insulin Revenue by Manufacturer (2019-2024)
    3.3 Global Biosimilar Insulin Average Price by Manufacturer (2019-2024)
    3.4 Market Share Analysis (2023)
        3.4.1 Producer Shipments of Biosimilar Insulin by Manufacturer Revenue ($MM) and Market Share (%): 2023
        3.4.2 Top 3 Biosimilar Insulin Manufacturer Market Share in 2023
        3.4.2 Top 6 Biosimilar Insulin Manufacturer Market Share in 2023
    3.5 Biosimilar Insulin Market: Overall Company Footprint Analysis
        3.5.1 Biosimilar Insulin Market: Region Footprint
        3.5.2 Biosimilar Insulin Market: Company Product Type Footprint
        3.5.3 Biosimilar Insulin Market: Company Product Application Footprint
    3.6 New Market Entrants and Barriers to Market Entry
    3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region
    4.1 Global Biosimilar Insulin Market Size by Region
        4.1.1 Global Biosimilar Insulin Sales Quantity by Region (2019-2030)
        4.1.2 Global Biosimilar Insulin Consumption Value by Region (2019-2030)
        4.1.3 Global Biosimilar Insulin Average Price by Region (2019-2030)
    4.2 North America Biosimilar Insulin Consumption Value (2019-2030)
    4.3 Europe Biosimilar Insulin Consumption Value (2019-2030)
    4.4 Asia-Pacific Biosimilar Insulin Consumption Value (2019-2030)
    4.5 South America Biosimilar Insulin Consumption Value (2019-2030)
    4.6 Middle East and Africa Biosimilar Insulin Consumption Value (2019-2030)

5 Market Segment by Type
    5.1 Global Biosimilar Insulin Sales Quantity by Type (2019-2030)
    5.2 Global Biosimilar Insulin Consumption Value by Type (2019-2030)
    5.3 Global Biosimilar Insulin Average Price by Type (2019-2030)

6 Market Segment by Distribution Channel
    6.1 Global Biosimilar Insulin Sales Quantity by Distribution Channel (2019-2030)
    6.2 Global Biosimilar Insulin Consumption Value by Distribution Channel (2019-2030)
    6.3 Global Biosimilar Insulin Average Price by Distribution Channel (2019-2030)

7 North America
    7.1 North America Biosimilar Insulin Sales Quantity by Type (2019-2030)
    7.2 North America Biosimilar Insulin Sales Quantity by Distribution Channel (2019-2030)
    7.3 North America Biosimilar Insulin Market Size by Country
        7.3.1 North America Biosimilar Insulin Sales Quantity by Country (2019-2030)
        7.3.2 North America Biosimilar Insulin Consumption Value by Country (2019-2030)
        7.3.3 United States Market Size and Forecast (2019-2030)
        7.3.4 Canada Market Size and Forecast (2019-2030)
        7.3.5 Mexico Market Size and Forecast (2019-2030)

8 Europe
    8.1 Europe Biosimilar Insulin Sales Quantity by Type (2019-2030)
    8.2 Europe Biosimilar Insulin Sales Quantity by Distribution Channel (2019-2030)
    8.3 Europe Biosimilar Insulin Market Size by Country
        8.3.1 Europe Biosimilar Insulin Sales Quantity by Country (2019-2030)
        8.3.2 Europe Biosimilar Insulin Consumption Value by Country (2019-2030)
        8.3.3 Germany Market Size and Forecast (2019-2030)
        8.3.4 France Market Size and Forecast (2019-2030)
        8.3.5 United Kingdom Market Size and Forecast (2019-2030)
        8.3.6 Russia Market Size and Forecast (2019-2030)
        8.3.7 Italy Market Size and Forecast (2019-2030)

9 Asia-Pacific
    9.1 Asia-Pacific Biosimilar Insulin Sales Quantity by Type (2019-2030)
    9.2 Asia-Pacific Biosimilar Insulin Sales Quantity by Distribution Channel (2019-2030)
    9.3 Asia-Pacific Biosimilar Insulin Market Size by Region
        9.3.1 Asia-Pacific Biosimilar Insulin Sales Quantity by Region (2019-2030)
        9.3.2 Asia-Pacific Biosimilar Insulin Consumption Value by Region (2019-2030)
        9.3.3 China Market Size and Forecast (2019-2030)
        9.3.4 Japan Market Size and Forecast (2019-2030)
        9.3.5 Korea Market Size and Forecast (2019-2030)
        9.3.6 India Market Size and Forecast (2019-2030)
        9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
        9.3.8 Australia Market Size and Forecast (2019-2030)

10 South America
    10.1 South America Biosimilar Insulin Sales Quantity by Type (2019-2030)
    10.2 South America Biosimilar Insulin Sales Quantity by Distribution Channel (2019-2030)
    10.3 South America Biosimilar Insulin Market Size by Country
        10.3.1 South America Biosimilar Insulin Sales Quantity by Country (2019-2030)
        10.3.2 South America Biosimilar Insulin Consumption Value by Country (2019-2030)
        10.3.3 Brazil Market Size and Forecast (2019-2030)
        10.3.4 Argentina Market Size and Forecast (2019-2030)

11 Middle East & Africa
    11.1 Middle East & Africa Biosimilar Insulin Sales Quantity by Type (2019-2030)
    11.2 Middle East & Africa Biosimilar Insulin Sales Quantity by Distribution Channel (2019-2030)
    11.3 Middle East & Africa Biosimilar Insulin Market Size by Country
        11.3.1 Middle East & Africa Biosimilar Insulin Sales Quantity by Country (2019-2030)
        11.3.2 Middle East & Africa Biosimilar Insulin Consumption Value by Country (2019-2030)
        11.3.3 Turkey Market Size and Forecast (2019-2030)
        11.3.4 Egypt Market Size and Forecast (2019-2030)
        11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
        11.3.6 South Africa Market Size and Forecast (2019-2030)

12 Market Dynamics
    12.1 Biosimilar Insulin Market Drivers
    12.2 Biosimilar Insulin Market Restraints
    12.3 Biosimilar Insulin Trends Analysis
    12.4 Porters Five Forces Analysis
        12.4.1 Threat of New Entrants
        12.4.2 Bargaining Power of Suppliers
        12.4.3 Bargaining Power of Buyers
        12.4.4 Threat of Substitutes
        12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain
    13.1 Raw Material of Biosimilar Insulin and Key Manufacturers
    13.2 Manufacturing Costs Percentage of Biosimilar Insulin
    13.3 Biosimilar Insulin Production Process
    13.4 Biosimilar Insulin Industrial Chain

14 Shipments by Distribution Channel
    14.1 Sales Channel
        14.1.1 Direct to End-User
        14.1.2 Distributors
    14.2 Biosimilar Insulin Typical Distributors
    14.3 Biosimilar Insulin Typical Customers

15 Research Findings and Conclusion

16 Appendix
    16.1 Methodology
    16.2 Research Process and Data Source
    16.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Biosimilar Insulin Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Table 2. Global Biosimilar Insulin Consumption Value by Distribution Channel, (USD Million), 2019 & 2023 & 2030
    Table 3. Eli Lilly Basic Information, Manufacturing Base and Competitors
    Table 4. Eli Lilly Major Business
    Table 5. Eli Lilly Biosimilar Insulin Product and Services
    Table 6. Eli Lilly Biosimilar Insulin Sales Quantity (K Unit), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 7. Eli Lilly Recent Developments/Updates
    Table 8. Sanofi Basic Information, Manufacturing Base and Competitors
    Table 9. Sanofi Major Business
    Table 10. Sanofi Biosimilar Insulin Product and Services
    Table 11. Sanofi Biosimilar Insulin Sales Quantity (K Unit), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 12. Sanofi Recent Developments/Updates
    Table 13. Gan&Lee Basic Information, Manufacturing Base and Competitors
    Table 14. Gan&Lee Major Business
    Table 15. Gan&Lee Biosimilar Insulin Product and Services
    Table 16. Gan&Lee Biosimilar Insulin Sales Quantity (K Unit), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 17. Gan&Lee Recent Developments/Updates
    Table 18. Tonghua Dongbao Basic Information, Manufacturing Base and Competitors
    Table 19. Tonghua Dongbao Major Business
    Table 20. Tonghua Dongbao Biosimilar Insulin Product and Services
    Table 21. Tonghua Dongbao Biosimilar Insulin Sales Quantity (K Unit), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 22. Tonghua Dongbao Recent Developments/Updates
    Table 23. United Laboratory Basic Information, Manufacturing Base and Competitors
    Table 24. United Laboratory Major Business
    Table 25. United Laboratory Biosimilar Insulin Product and Services
    Table 26. United Laboratory Biosimilar Insulin Sales Quantity (K Unit), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 27. United Laboratory Recent Developments/Updates
    Table 28. Geropharm Basic Information, Manufacturing Base and Competitors
    Table 29. Geropharm Major Business
    Table 30. Geropharm Biosimilar Insulin Product and Services
    Table 31. Geropharm Biosimilar Insulin Sales Quantity (K Unit), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 32. Geropharm Recent Developments/Updates
    Table 33. Biocon Basic Information, Manufacturing Base and Competitors
    Table 34. Biocon Major Business
    Table 35. Biocon Biosimilar Insulin Product and Services
    Table 36. Biocon Biosimilar Insulin Sales Quantity (K Unit), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 37. Biocon Recent Developments/Updates
    Table 38. Wockhardt Basic Information, Manufacturing Base and Competitors
    Table 39. Wockhardt Major Business
    Table 40. Wockhardt Biosimilar Insulin Product and Services
    Table 41. Wockhardt Biosimilar Insulin Sales Quantity (K Unit), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 42. Wockhardt Recent Developments/Updates
    Table 43. Global Biosimilar Insulin Sales Quantity by Manufacturer (2019-2024) & (K Unit)
    Table 44. Global Biosimilar Insulin Revenue by Manufacturer (2019-2024) & (USD Million)
    Table 45. Global Biosimilar Insulin Average Price by Manufacturer (2019-2024) & (US$/Unit)
    Table 46. Market Position of Manufacturers in Biosimilar Insulin, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
    Table 47. Head Office and Biosimilar Insulin Production Site of Key Manufacturer
    Table 48. Biosimilar Insulin Market: Company Product Type Footprint
    Table 49. Biosimilar Insulin Market: Company Product Application Footprint
    Table 50. Biosimilar Insulin New Market Entrants and Barriers to Market Entry
    Table 51. Biosimilar Insulin Mergers, Acquisition, Agreements, and Collaborations
    Table 52. Global Biosimilar Insulin Sales Quantity by Region (2019-2024) & (K Unit)
    Table 53. Global Biosimilar Insulin Sales Quantity by Region (2025-2030) & (K Unit)
    Table 54. Global Biosimilar Insulin Consumption Value by Region (2019-2024) & (USD Million)
    Table 55. Global Biosimilar Insulin Consumption Value by Region (2025-2030) & (USD Million)
    Table 56. Global Biosimilar Insulin Average Price by Region (2019-2024) & (US$/Unit)
    Table 57. Global Biosimilar Insulin Average Price by Region (2025-2030) & (US$/Unit)
    Table 58. Global Biosimilar Insulin Sales Quantity by Type (2019-2024) & (K Unit)
    Table 59. Global Biosimilar Insulin Sales Quantity by Type (2025-2030) & (K Unit)
    Table 60. Global Biosimilar Insulin Consumption Value by Type (2019-2024) & (USD Million)
    Table 61. Global Biosimilar Insulin Consumption Value by Type (2025-2030) & (USD Million)
    Table 62. Global Biosimilar Insulin Average Price by Type (2019-2024) & (US$/Unit)
    Table 63. Global Biosimilar Insulin Average Price by Type (2025-2030) & (US$/Unit)
    Table 64. Global Biosimilar Insulin Sales Quantity by Distribution Channel (2019-2024) & (K Unit)
    Table 65. Global Biosimilar Insulin Sales Quantity by Distribution Channel (2025-2030) & (K Unit)
    Table 66. Global Biosimilar Insulin Consumption Value by Distribution Channel (2019-2024) & (USD Million)
    Table 67. Global Biosimilar Insulin Consumption Value by Distribution Channel (2025-2030) & (USD Million)
    Table 68. Global Biosimilar Insulin Average Price by Distribution Channel (2019-2024) & (US$/Unit)
    Table 69. Global Biosimilar Insulin Average Price by Distribution Channel (2025-2030) & (US$/Unit)
    Table 70. North America Biosimilar Insulin Sales Quantity by Type (2019-2024) & (K Unit)
    Table 71. North America Biosimilar Insulin Sales Quantity by Type (2025-2030) & (K Unit)
    Table 72. North America Biosimilar Insulin Sales Quantity by Distribution Channel (2019-2024) & (K Unit)
    Table 73. North America Biosimilar Insulin Sales Quantity by Distribution Channel (2025-2030) & (K Unit)
    Table 74. North America Biosimilar Insulin Sales Quantity by Country (2019-2024) & (K Unit)
    Table 75. North America Biosimilar Insulin Sales Quantity by Country (2025-2030) & (K Unit)
    Table 76. North America Biosimilar Insulin Consumption Value by Country (2019-2024) & (USD Million)
    Table 77. North America Biosimilar Insulin Consumption Value by Country (2025-2030) & (USD Million)
    Table 78. Europe Biosimilar Insulin Sales Quantity by Type (2019-2024) & (K Unit)
    Table 79. Europe Biosimilar Insulin Sales Quantity by Type (2025-2030) & (K Unit)
    Table 80. Europe Biosimilar Insulin Sales Quantity by Distribution Channel (2019-2024) & (K Unit)
    Table 81. Europe Biosimilar Insulin Sales Quantity by Distribution Channel (2025-2030) & (K Unit)
    Table 82. Europe Biosimilar Insulin Sales Quantity by Country (2019-2024) & (K Unit)
    Table 83. Europe Biosimilar Insulin Sales Quantity by Country (2025-2030) & (K Unit)
    Table 84. Europe Biosimilar Insulin Consumption Value by Country (2019-2024) & (USD Million)
    Table 85. Europe Biosimilar Insulin Consumption Value by Country (2025-2030) & (USD Million)
    Table 86. Asia-Pacific Biosimilar Insulin Sales Quantity by Type (2019-2024) & (K Unit)
    Table 87. Asia-Pacific Biosimilar Insulin Sales Quantity by Type (2025-2030) & (K Unit)
    Table 88. Asia-Pacific Biosimilar Insulin Sales Quantity by Distribution Channel (2019-2024) & (K Unit)
    Table 89. Asia-Pacific Biosimilar Insulin Sales Quantity by Distribution Channel (2025-2030) & (K Unit)
    Table 90. Asia-Pacific Biosimilar Insulin Sales Quantity by Region (2019-2024) & (K Unit)
    Table 91. Asia-Pacific Biosimilar Insulin Sales Quantity by Region (2025-2030) & (K Unit)
    Table 92. Asia-Pacific Biosimilar Insulin Consumption Value by Region (2019-2024) & (USD Million)
    Table 93. Asia-Pacific Biosimilar Insulin Consumption Value by Region (2025-2030) & (USD Million)
    Table 94. South America Biosimilar Insulin Sales Quantity by Type (2019-2024) & (K Unit)
    Table 95. South America Biosimilar Insulin Sales Quantity by Type (2025-2030) & (K Unit)
    Table 96. South America Biosimilar Insulin Sales Quantity by Distribution Channel (2019-2024) & (K Unit)
    Table 97. South America Biosimilar Insulin Sales Quantity by Distribution Channel (2025-2030) & (K Unit)
    Table 98. South America Biosimilar Insulin Sales Quantity by Country (2019-2024) & (K Unit)
    Table 99. South America Biosimilar Insulin Sales Quantity by Country (2025-2030) & (K Unit)
    Table 100. South America Biosimilar Insulin Consumption Value by Country (2019-2024) & (USD Million)
    Table 101. South America Biosimilar Insulin Consumption Value by Country (2025-2030) & (USD Million)
    Table 102. Middle East & Africa Biosimilar Insulin Sales Quantity by Type (2019-2024) & (K Unit)
    Table 103. Middle East & Africa Biosimilar Insulin Sales Quantity by Type (2025-2030) & (K Unit)
    Table 104. Middle East & Africa Biosimilar Insulin Sales Quantity by Distribution Channel (2019-2024) & (K Unit)
    Table 105. Middle East & Africa Biosimilar Insulin Sales Quantity by Distribution Channel (2025-2030) & (K Unit)
    Table 106. Middle East & Africa Biosimilar Insulin Sales Quantity by Region (2019-2024) & (K Unit)
    Table 107. Middle East & Africa Biosimilar Insulin Sales Quantity by Region (2025-2030) & (K Unit)
    Table 108. Middle East & Africa Biosimilar Insulin Consumption Value by Region (2019-2024) & (USD Million)
    Table 109. Middle East & Africa Biosimilar Insulin Consumption Value by Region (2025-2030) & (USD Million)
    Table 110. Biosimilar Insulin Raw Material
    Table 111. Key Manufacturers of Biosimilar Insulin Raw Materials
    Table 112. Biosimilar Insulin Typical Distributors
    Table 113. Biosimilar Insulin Typical Customers
List of Figures
    Figure 1. Biosimilar Insulin Picture
    Figure 2. Global Biosimilar Insulin Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 3. Global Biosimilar Insulin Consumption Value Market Share by Type in 2023
    Figure 4. Biosimilar Insulin Glargine Examples
    Figure 5. Biosimilar Insulin Lispro Examples
    Figure 6. Other Examples
    Figure 7. Global Biosimilar Insulin Consumption Value by Distribution Channel, (USD Million), 2019 & 2023 & 2030
    Figure 8. Global Biosimilar Insulin Consumption Value Market Share by Distribution Channel in 2023
    Figure 9. Hospital Examples
    Figure 10. Retail Pharmacy Examples
    Figure 11. Others Examples
    Figure 12. Global Biosimilar Insulin Consumption Value, (USD Million): 2019 & 2023 & 2030
    Figure 13. Global Biosimilar Insulin Consumption Value and Forecast (2019-2030) & (USD Million)
    Figure 14. Global Biosimilar Insulin Sales Quantity (2019-2030) & (K Unit)
    Figure 15. Global Biosimilar Insulin Average Price (2019-2030) & (US$/Unit)
    Figure 16. Global Biosimilar Insulin Sales Quantity Market Share by Manufacturer in 2023
    Figure 17. Global Biosimilar Insulin Consumption Value Market Share by Manufacturer in 2023
    Figure 18. Producer Shipments of Biosimilar Insulin by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
    Figure 19. Top 3 Biosimilar Insulin Manufacturer (Consumption Value) Market Share in 2023
    Figure 20. Top 6 Biosimilar Insulin Manufacturer (Consumption Value) Market Share in 2023
    Figure 21. Global Biosimilar Insulin Sales Quantity Market Share by Region (2019-2030)
    Figure 22. Global Biosimilar Insulin Consumption Value Market Share by Region (2019-2030)
    Figure 23. North America Biosimilar Insulin Consumption Value (2019-2030) & (USD Million)
    Figure 24. Europe Biosimilar Insulin Consumption Value (2019-2030) & (USD Million)
    Figure 25. Asia-Pacific Biosimilar Insulin Consumption Value (2019-2030) & (USD Million)
    Figure 26. South America Biosimilar Insulin Consumption Value (2019-2030) & (USD Million)
    Figure 27. Middle East & Africa Biosimilar Insulin Consumption Value (2019-2030) & (USD Million)
    Figure 28. Global Biosimilar Insulin Sales Quantity Market Share by Type (2019-2030)
    Figure 29. Global Biosimilar Insulin Consumption Value Market Share by Type (2019-2030)
    Figure 30. Global Biosimilar Insulin Average Price by Type (2019-2030) & (US$/Unit)
    Figure 31. Global Biosimilar Insulin Sales Quantity Market Share by Distribution Channel (2019-2030)
    Figure 32. Global Biosimilar Insulin Consumption Value Market Share by Distribution Channel (2019-2030)
    Figure 33. Global Biosimilar Insulin Average Price by Distribution Channel (2019-2030) & (US$/Unit)
    Figure 34. North America Biosimilar Insulin Sales Quantity Market Share by Type (2019-2030)
    Figure 35. North America Biosimilar Insulin Sales Quantity Market Share by Distribution Channel (2019-2030)
    Figure 36. North America Biosimilar Insulin Sales Quantity Market Share by Country (2019-2030)
    Figure 37. North America Biosimilar Insulin Consumption Value Market Share by Country (2019-2030)
    Figure 38. United States Biosimilar Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 39. Canada Biosimilar Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 40. Mexico Biosimilar Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 41. Europe Biosimilar Insulin Sales Quantity Market Share by Type (2019-2030)
    Figure 42. Europe Biosimilar Insulin Sales Quantity Market Share by Distribution Channel (2019-2030)
    Figure 43. Europe Biosimilar Insulin Sales Quantity Market Share by Country (2019-2030)
    Figure 44. Europe Biosimilar Insulin Consumption Value Market Share by Country (2019-2030)
    Figure 45. Germany Biosimilar Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 46. France Biosimilar Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 47. United Kingdom Biosimilar Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 48. Russia Biosimilar Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 49. Italy Biosimilar Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 50. Asia-Pacific Biosimilar Insulin Sales Quantity Market Share by Type (2019-2030)
    Figure 51. Asia-Pacific Biosimilar Insulin Sales Quantity Market Share by Distribution Channel (2019-2030)
    Figure 52. Asia-Pacific Biosimilar Insulin Sales Quantity Market Share by Region (2019-2030)
    Figure 53. Asia-Pacific Biosimilar Insulin Consumption Value Market Share by Region (2019-2030)
    Figure 54. China Biosimilar Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 55. Japan Biosimilar Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 56. Korea Biosimilar Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 57. India Biosimilar Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 58. Southeast Asia Biosimilar Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 59. Australia Biosimilar Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 60. South America Biosimilar Insulin Sales Quantity Market Share by Type (2019-2030)
    Figure 61. South America Biosimilar Insulin Sales Quantity Market Share by Distribution Channel (2019-2030)
    Figure 62. South America Biosimilar Insulin Sales Quantity Market Share by Country (2019-2030)
    Figure 63. South America Biosimilar Insulin Consumption Value Market Share by Country (2019-2030)
    Figure 64. Brazil Biosimilar Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 65. Argentina Biosimilar Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 66. Middle East & Africa Biosimilar Insulin Sales Quantity Market Share by Type (2019-2030)
    Figure 67. Middle East & Africa Biosimilar Insulin Sales Quantity Market Share by Distribution Channel (2019-2030)
    Figure 68. Middle East & Africa Biosimilar Insulin Sales Quantity Market Share by Region (2019-2030)
    Figure 69. Middle East & Africa Biosimilar Insulin Consumption Value Market Share by Region (2019-2030)
    Figure 70. Turkey Biosimilar Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 71. Egypt Biosimilar Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 72. Saudi Arabia Biosimilar Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 73. South Africa Biosimilar Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 74. Biosimilar Insulin Market Drivers
    Figure 75. Biosimilar Insulin Market Restraints
    Figure 76. Biosimilar Insulin Market Trends
    Figure 77. Porters Five Forces Analysis
    Figure 78. Manufacturing Cost Structure Analysis of Biosimilar Insulin in 2023
    Figure 79. Manufacturing Process Analysis of Biosimilar Insulin
    Figure 80. Biosimilar Insulin Industrial Chain
    Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
    Figure 82. Direct Channel Pros & Cons
    Figure 83. Indirect Channel Pros & Cons
    Figure 84. Methodology
    Figure 85. Research Process and Data Source

Companies Mentioned

Eli Lilly
Sanofi
Gan&Lee
Tonghua Dongbao
United Laboratory
Geropharm
Biocon
Wockhardt